Showing 712 results
-
Press release /The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…
-
Press release /Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
-
Press release /Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced…
-
Press release /Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis…
-
Press release /With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
-
Press release /China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis Moderate-to-severe plaque…
-
Press release /Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1 Detailed…
-
Press release /At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Press release /At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared…
-
Press release /Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…